Veeda opens Ph I unit in Malaysia

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial, Contract research organization

India’s Veeda Clinical Research has set up a Phase I unit in Malaysia, joining the growing list of contract research organisations (CRO) attracted to the country.

The new 28 bed unit, which is located at Ampang Hospital in the capital Kuala Lumpur, will provide support for early-stage clinical development projects, the first of which are due to start in the next few months.

Veeda set up the facility in collaboration with a team from Malaysian Ministry of Health which, according to group medical director Maurice Cross, was critical to its successful completion.

Without the help and support of Tan Sri Ismail Merican, the then Medical Director General, Dr Lim Tek Ono and Dato’ SC Teoh in the early days this project would never have got started.”

This was echoed by Goh Pik Pin from the Ministry of Health, who added that: “It is very difficult, sometimes, to integrate the approaches of private CROs and Governmental agencies but…we have succeeded and now look forward to beginning a planned series of studies intended to stretch and develop the Unit's capabilities."

Malaysia pharma development

The Malaysian Government has courted​ the contract research sector in the last few years in an effort to strengthen its clinical infrastructure in

This has seen, since 2009, companies such as Kendle​, Novotech​, Quintiles​ and, most recently, Siro Clinpharm​ set up a variety of early and late-stage clinical research capabilities in the country.

Veeda, like all of the other recent additions to the Malaysian research sector, cited the rules that govern clinical trials in the country as particularly attractive and a key driver for the investment;.

It said that: “Regulatory and start-up times in Malaysia are very favourable even when compared with the Western Countries and are far faster than many evolving countries.”

The firm also said that the National Disease Registry as a key factor in the decision, explaining that it makes the identification of patient populations “especially easy and efficient​."

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more